Phreesia, Inc. provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers an appointment scheduling system for online appointments, reminders, and referral tracking and management; registration solutions to automate patient self-registration; revenue cycle solutions that provide insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network solutions to deliver clinically relevant content to patients. It deploys its platform in a range of modalities, including Phreesia Mobile, a patients’ mobile device; PhreesiaPads, a self-service intake tablets; Phreesia Dashboard, a web-based dashboard for healthcare services clients; and Arrivals Kiosks, which are on-site kiosks. The company serves a range of healthcare services clients, including single-specialty practices, multi-specialty groups, and health systems; and pharmaceutical, medical device, and biotechnology companies, as well as government entities and other organizations. Phreesia, Inc. was incorporated in 2005 and is based in Wilmington, Delaware.
Future Prospects | Analyst price targets range from $32 to $35, reflecting optimism about Phreesia's growth potential in the evolving digital health landscape |
Market Expansion | Delve into Phreesia's success in securing large specialty provider networks and its comprehensive approach to digital health solutions |
Financial Trajectory | Explore Phreesia's path to profitability, with improving EBITDA and a strategic focus on becoming a Rule of 30+ profile company |
Digital Health Pionee | Phreesia leads in patient-facing software and pharma advertising, showcasing robust revenue growth and a strong gross margin in the healthcare IT secto |

Metrics to compare | PHR | Sector Sector - Average of metrics from a broad group of related Technology sector companies | Relationship RelationshipPHRPeersSector | |
|---|---|---|---|---|
P/E Ratio | −133.9x | −7.2x | −0.5x | |
PEG Ratio | −1.43 | 0.02 | 0.00 | |
Price / Book | 2.2x | 1.4x | 2.6x | |
Price / LTM Sales | 1.6x | 1.7x | 3.3x | |
Upside (Analyst Target) | 134.3% | 73.6% | 46.0% | |
Fair Value Upside | Unlock | 41.1% | 5.4% | Unlock |